ArticlePLoS currents2015
A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy.
Article in PLoS currents, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Multifocal cohort analysis unveils cell types associated with regional lymph node seeding in prostate cancer.Genome medicine · 2026Article
- Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes.European urology open science · 2026Article
- A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Observational
- Personalizing chemotherapy drug selection using a novel transcriptomic chemogram.PLoS computational biology · 2025Article
- Comprehensive bioinformatic analysis reveals prognostic significance and functional insights of candidate gene expression in colorectal cancer.Scientific reports · 2025Article
- 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer.Frontiers in oncology · 2025Article
- Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.International journal of cancer · 2024Review
- Biomarkers in Cancer Detection, Diagnosis, and Prognosis.Sensors (Basel, Switzerland) · 2023Review
- Aquaporins as Prognostic Biomarker in Prostate Cancer.Cancers · 2023Review
- Multi-Stage Classification-Based Deep Learning for Gleason System Grading Using Histopathological Images.Cancers · 2022Article
- Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks.Bioinformatics (Oxford, England) · 2022Article
- Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review.BMJ open · 2021Article
- A Deep Learning Pipeline for Grade Groups Classification Using Digitized Prostate Biopsy Specimens.Sensors (Basel, Switzerland) · 2021Article
- Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2.European urology focus · 2021Article
- Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.Scientific reports · 2021Article
- Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.JCO precision oncology · 2021Article
- Identifying and treating ROBO1The Prostate · 2020Article
- Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens.JAMA oncology · 2020Article
- Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.Journal of cancer research and clinical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among the estimated 230,000 men diagnosed with prostate cancer in the US each year there has been a rise in the number of radical prostatectomies (RP). There is some debate over the value of immediate adjuvant therapy following RP in men with high-risk pathological features versus delayed salvage radiation therapy when signs of disease progression are observed. Thus, it would be potentially useful to inform post-RP management strategies by more clearly identifying those patients at higher risk of progression and death from prostate cancer. A 22 gene-expression assay, Decipher® (GenomeDx Biosciences), has been developed in men treated with radical prostatectomy to predict the five-year risk of metastatic prostate cancer. Published and unpublished literature was evaluated to determine the analytic validity, clinical validity and clinical utility of Decipher. Limited information is available on the analytic validity of Decipher. In both discovery and validation studies, Decipher was shown to have good performance in discriminating men with metastasis from men without metastasis five years after surgery (AUC 0.75 to 0.90). In terms of clinical utility, no evidence was found reporting improved outcomes (lower prostate cancer specific mortality and treatment related adverse effects) from using this test to guide post-operative treatment. Four studies provided weak indirect evidence of clinical utility in which 31% to 43% of post-operative treatment recommendations were changed in men with high-risk prostate cancer based on test results, with 27% to 52% of treatment recommendations changing from any treatment to no treatment.
Identifiers
26664778PMC4659515W2343697216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.